Abstract
The oxidation of catechol metabolites (2-OH-E1 / 2 / 3 and 4-OH-E1 / 2 / 3) of the endogenous estrogen, i.e. estrone (E1), 17 beta-estradiol (E2), estriol (E3), gives rise to corresponding estrogen-2,3-quinone (E-2,3-Q) and estrogen-3,4- quinone (E-3,4-Q). These reactive estrogen metabolites form covalent adducts with DNA and quinone, and semi-quinone forms of catechol estrogens -induced DNA adducts are found in various target tissues of cancer. Catecholestrogen through redox cycling produce free radicals that also generate various forms of free radical-induced DNA damage. Interaction of estrogen-induced oxidants and estrogen metabolites with DNA has been shown to generate mutations in genes. Hypermethylation at CpG sites in specific regions of the genome coupled with estrogen-induced oxidative damage at CpG sites, predominantly in the hypermethylated regions, could also cause alterations in the genome of cells of estrogen target organs that lead to mutation of genes. Increasing evidence shows that estrogen through oxidative stress and / or its metabolic products induce genetic alteration affecting both the structural as well as function of the genes. Presence of multiple forms of genetic alterations such as chromosomal aberrations, gene amplifications, DNA sequence variations, and DNA microsatellite instability in estrogen-related cancers and induction of similar genetic events by estrogen both in vivo and in vitro indicate that genetic alterations play an important role in estrogen-related carcinogenesis. This review highlights the current understanding of the estrogen-induced genetic alterations and their significance in estrogen-related carcinogenesis.
Keywords: estrogen, reactive oxygen (nitrogen) species, genetic alterations, carcinogenicity
Current Genomics
Title: Estrogen-Induced Genetic Alterations and Their Role in Carcinogenicity
Volume: 5 Issue: 3
Author(s): D. Roy and K. P. Singh
Affiliation:
Keywords: estrogen, reactive oxygen (nitrogen) species, genetic alterations, carcinogenicity
Abstract: The oxidation of catechol metabolites (2-OH-E1 / 2 / 3 and 4-OH-E1 / 2 / 3) of the endogenous estrogen, i.e. estrone (E1), 17 beta-estradiol (E2), estriol (E3), gives rise to corresponding estrogen-2,3-quinone (E-2,3-Q) and estrogen-3,4- quinone (E-3,4-Q). These reactive estrogen metabolites form covalent adducts with DNA and quinone, and semi-quinone forms of catechol estrogens -induced DNA adducts are found in various target tissues of cancer. Catecholestrogen through redox cycling produce free radicals that also generate various forms of free radical-induced DNA damage. Interaction of estrogen-induced oxidants and estrogen metabolites with DNA has been shown to generate mutations in genes. Hypermethylation at CpG sites in specific regions of the genome coupled with estrogen-induced oxidative damage at CpG sites, predominantly in the hypermethylated regions, could also cause alterations in the genome of cells of estrogen target organs that lead to mutation of genes. Increasing evidence shows that estrogen through oxidative stress and / or its metabolic products induce genetic alteration affecting both the structural as well as function of the genes. Presence of multiple forms of genetic alterations such as chromosomal aberrations, gene amplifications, DNA sequence variations, and DNA microsatellite instability in estrogen-related cancers and induction of similar genetic events by estrogen both in vivo and in vitro indicate that genetic alterations play an important role in estrogen-related carcinogenesis. This review highlights the current understanding of the estrogen-induced genetic alterations and their significance in estrogen-related carcinogenesis.
Export Options
About this article
Cite this article as:
Roy D. and Singh P. K., Estrogen-Induced Genetic Alterations and Their Role in Carcinogenicity, Current Genomics 2004; 5 (3) . https://dx.doi.org/10.2174/1389202043349471
DOI https://dx.doi.org/10.2174/1389202043349471 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Cancer Potential of a Novel SERM Ormeloxifene
Current Medicinal Chemistry Editorial: Drug Targets and Biomarkers for Obstetric/Gynecologic/Reproductive Diseases
Current Drug Targets Leptin, Estrogens and Cancer
Mini-Reviews in Medicinal Chemistry Host Pharmacogenetics in the Treatment of HIV and Cancer
Current Drug Safety Cisplatin Changes Expression of SEMA3B in Endometrial Cancer
Current Pharmaceutical Biotechnology Genomic Approaches and Oxygen Radical Measurement as Biomarker Candidates of Off-Season Predictor of Pollinosis: A Pilot Study
Current Pharmacogenomics and Personalized Medicine LHRH-Targeted Drug Delivery Systems for Cancer Therapy
Mini-Reviews in Medicinal Chemistry A Review of the Three-Dimensional Cell Culture Technique: Approaches, Advantages and Applications
Current Stem Cell Research & Therapy Technetium-99m-based Radiopharmaceuticals in Sentinel Lymph Node Biopsy: Gynecologic Oncology Perspective
Current Pharmaceutical Design Female Infertility and Assisted Reproduction: Impact of Oxidative Stress-- An Update
Current Women`s Health Reviews “Smart” Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems
Drug Delivery Letters Cdc25A Protein Phosphatase: A Therapeutic Target for Liver Cancer Therapies
Anti-Cancer Agents in Medicinal Chemistry Editorial [ Hot Topic:New Frontiers in Female Reproduction and Fertility (Executive Guest Editor: Sandra Cecconi)]
Current Pharmaceutical Design Hypoxia and Fetal Heart Development
Current Molecular Medicine A Comprehensive Overview of Colon Cancer- A Grim Reaper of the 21st Century
Current Medicinal Chemistry Pharmacokinetics, Organ Toxicity and Antitumor Activity of Docetaxel Loaded in Folate Targeted Cholesterol Based Micelles
Current Drug Delivery Elastic Liposomes for Topical and Transdermal Drug Delivery
Current Drug Delivery Pharmacological Inhibitors of Fatty Acid Synthase (FASN)-Catalyzed Endogenous Fatty Acid Biogenesis: A New Family of Anti-Cancer Agents?
Current Pharmaceutical Biotechnology Imaging Cellular Receptors in Breast Cancers: An Overview
Current Pharmaceutical Biotechnology PI3K/Akt/JNK/c-Jun Signaling Pathway is a Mediator for Arsenite- Induced Cyclin D1 Expression and Cell Growth in Human Bronchial Epithelial Cells
Current Cancer Drug Targets